Lab Glassware Division 中文(Chinese)

An HPLC-UV Method for Determination of Antitussives

Method: HPLC
Matrix: Medicine
Application No.: 101948
Componds: Butetamate citrate, Dextromethorphan hydrobromide, Oxeladin citrate, Carbetapentane citrate, Cloperastine hydrochloride
Columns: Inspire C18 5 μm 250 x 4.6 mm
Cat No.: 81006
Sample Pretreatment: Samples: Stock solution of each antitussive was prepared in acetonitrile at a concentration of 1 mg/mL.A combined working solution was freshly obtained by dilution of stock solution with mobile phase.
Conditions: Mobile Phase:
A: 30 mM potassium phosphate monobasic, pH 2.5
B: acetonitrile:methanol = 4 / 6
Gradient: 53%B hold 3min, 53 to 70%B in 5min, 70 to 80%B in 1min, hold2min, 80 to 53%B in 1min, equilibrate at 53%B for 3 min
Flow Rate: 1.0 mL/min;
Injection: 10 µL;
Temperature: 30 ℃;
Wavelength: 220nm
Publisher: Dikma Technologies Inc.
Keyword: Butetamate citrate, Dextromethorphan hydrobromide, Oxeladin citrate, Carbetapentane citrate, Cloperastine hydrochloride, Antitussives, HPLC-UV
Abstract: All five compounds were well separated on a DIKMA Inspire C18 Column(Cat#81006) within 11 mins using a simple and robust HPLC-UV method.

 

No.

Compound

Molecular Formula

Concentration (µg/mL)

Retention Time(min)

Resolution

1

Butetamate citrate

C22H33NO9

100

5.416

-

2

Dextromethorphan hydrobromide

C18H26BrNO

50

5.731

1.65

3

Oxeladin citrate

C26H41NO10

150

9.285

19.12

4

Carbetapentane citrate

C26H39NO10

100

9.811

3.03

5

Cloperastine hydrochloride

C20H25Cl2NO

40

10.241

2.61